IL2RA and neoplasm: Some newly developed fusion proteins that comprise IL-2 and IL-2Rα, such as ALKS 4230, could selectively active the effector cells bearing intermediate receptors, and exhibit superior tumor control efficacy and less toxicity in mouse tumor models [103].